discoveri
develop
new
highli
potent
anticoronaviru
agent
effect
approach
control
potenti
emerg
epidem
coronavirus
still
remain
import
mission
identifi
tylophorin
compound
includ
natur
occur
synthet
phenanthroindolizidin
phenanthroquinolizidin
potent
vitro
inhibitor
enteropathogen
coronaviru
transmiss
gastroenter
viru
tgev
potent
compound
show
maxim
effect
concentr
ec
valu
rang
nm
determin
immunofluoresc
assay
express
tgev
n
protein
real
timequantit
pcr
analysi
viral
yield
furthermor
potent
tylophorin
compound
exert
profound
antitgev
replic
activ
therebi
block
tgevinduc
apoptosi
subsequ
cytopath
effect
st
cell
analysi
structureact
relat
indic
activ
tylophorin
analogu
compound
hydroxyl
group
posit
indolizidin
moieti
posit
phenanthren
moieti
quinolizidin
counterpart
potent
indolizidin
addit
tylophorin
compound
strongli
reduc
cytopath
effect
vero
cell
induc
human
sever
acut
respiratori
syndrom
coronaviru
sar
cov
ec
valu
rang
less
nm
moreov
pharmacokinet
studi
demonstr
high
compar
oral
bioavail
natur
occur
tylophorin
rat
thu
result
suggest
tylophorin
compound
novel
potent
anticoronaviru
agent
may
develop
therapeut
agent
treat
tgev
sar
cov
infect
coronavirus
envelop
virus
positivesens
singlestrand
rna
genom
helic
symmetri
anim
virus
belong
famili
coronavirida
divid
three
group
base
serolog
crossreact
confirm
genom
sequenc
analysi
group
coronavirus
includ
anim
pathogen
porcin
transmiss
gastroenter
coronaviru
tgev
human
coronavirus
group
ii
also
includ
pathogen
veterinari
relev
murin
coronaviru
mous
hepat
viru
mhv
jhm
strain
human
sever
acut
respiratori
syndrom
coronaviru
sar
cov
well
group
iii
includ
avian
coronavirus
weiss
navasmartin
primarili
infect
upper
respiratori
gastrointestin
tract
bird
mammal
brian
baric
vaccin
current
avail
anim
coronavirus
vaccin
efficaci
other
caus
advers
side
effect
instanc
vaccin
felin
coronavirus
exacerb
diseas
vaccin
anim
expos
wildtyp
viru
olsen
moreov
antibodi
enhanc
diseas
potenti
risk
sar
cov
vaccin
human
weiss
navasmartin
although
case
sar
report
sinc
april
natur
unpredict
outbreak
sar
cov
see
front
matter
elsevi
bv
right
reserv
still
potenti
threat
global
economi
public
health
weiss
navasmartin
effect
therapi
exist
sar
cov
infect
despit
tremend
effort
invest
find
antisar
cov
drug
includ
target
sar
covspecif
main
proteas
viral
attach
entri
fusion
intervent
thu
sar
cov
variant
thereof
could
easili
remerg
caus
diseas
discoveri
develop
new
highli
potent
anticoronaviru
agent
effect
approach
control
potenti
emerg
epidem
coronavirus
remain
import
mission
phenanthroindolizidin
alkaloid
tylophorin
tylocrebrin
tylophorinin
characterist
constitu
cynanchum
pergularia
tylophora
genera
asclepiadacea
phenanthroindolizidin
activ
leukemia
asthma
anaphylaxi
inflamm
bacteri
infect
bhutani
et
al
chemler
gopalakrishnan
et
al
well
cancer
li
et
al
staerk
et
al
yang
et
al
yang
et
al
herbal
plant
tylophora
indica
tradit
use
india
folk
remedi
treat
bronchial
asthma
bronchiti
rheumat
dermat
li
et
al
clinic
trial
six
tylophora
leav
one
per
day
efficaci
herbal
medicin
asthma
shivpuri
et
al
tylophora
ovata
use
tradit
herbal
medicin
rheumat
asthma
even
traumat
injuri
even
though
possess
mildli
toxic
properti
lin
phenanthroquinolizidin
typifi
cryptopleurin
isol
boehmeria
siamensi
chemic
synthesi
anticanc
antiinflammatori
activ
chuang
et
al
li
et
al
luo
et
al
yang
et
al
tylophora
plant
use
altern
medicin
deriv
alkaloid
extens
investig
drug
develop
chemler
report
discoveri
synthesi
isol
identif
tylophorin
compound
novel
potent
inhibitor
tgev
sar
cov
structureact
relat
also
analyz
inhibit
tgev
sar
cov
tylophorin
compound
high
potenc
vitro
low
nanomolar
rang
high
oral
avail
rat
suggest
may
potenti
therapeut
agent
coronaviru
infect
tgev
sar
cov
cell
virus
immunofluoresc
assay
ifa
cytopath
effect
cpe
swine
testicular
st
epitheli
cell
taiwan
fieldisol
virul
strain
tgev
grown
propag
describ
yang
et
al
ifa
cpe
cytotox
assay
also
describ
yang
et
al
briefli
st
cell
plate
without
h
pretreat
test
compound
infect
tgev
multipl
infect
moi
ifa
ifa
perform
h
postinfect
hpi
antibodi
spike
nucleocapsid
n
protein
tgev
cell
treat
differ
concentr
test
compound
result
assay
use
obtain
doserespons
curv
maxim
effect
concentr
ec
valu
determin
cpe
assay
tgev
inocul
monolay
st
cell
plate
moi
cpe
determin
hpi
detect
antitgev
activ
tgevinduc
cpe
character
round
enlarg
cell
format
syncytia
detach
cell
medium
result
present
repres
least
independ
experi
cytotox
assay
st
cell
cultur
minim
essenti
medium
invitrogen
inc
fetal
bovin
serum
hyclon
co
plate
treat
differ
concentr
test
compound
h
result
doserespons
curv
use
determin
maxim
cytotox
concentr
cc
valu
vero
cell
sar
cov
urbani
strain
grown
propag
describ
barnard
et
al
sar
covrel
cpe
inhibit
neutral
red
uptak
assay
determin
antivir
efficaci
ec
compound
cytotox
cc
perform
describ
barnard
et
al
chemic
western
blot
analysi
viral
rna
isol
rel
quantif
realtim
rtpcr
assay
perform
describ
yang
et
al
antibodi
human
gapdh
purchas
cell
signal
technolog
inc
usa
dmso
dma
purchas
sigma
aldrich
inc
mo
usa
infergen
tm
interferon
lot
kindli
provid
intermun
inc
brisban
ca
spraguedawley
rat
pharmacokinet
studi
obtain
biolasco
taiwan
co
ilan
taiwan
hous
anim
facil
nation
health
research
institut
taiwan
anim
studi
perform
accord
committeeapprov
procedur
male
rat
g
week
old
quarantin
week
use
anim
surgic
implant
jugularvein
cannula
day
treatment
fast
treatment
compound
given
rat
n
mgkg
intraven
oral
administr
prepar
mixtur
vv
intraven
oral
administr
dma
oral
administr
mixtur
vv
intraven
administr
volum
dose
solut
given
adjust
accord
bodi
weight
record
drug
administ
immedi
dose
intraven
min
h
compound
administr
blood
sampl
l
taken
anim
via
jugularvein
cannula
store
ice
c
process
plasma
subsequ
analysi
highperform
liquid
chromatographytandem
mass
spectrometri
hplcm
describ
yao
et
al
plasma
concentr
data
analyz
standard
noncompartment
method
kinetica
softwar
innaphas
philadelphia
pa
usa
tylophorin
analogu
prepar
describ
chuang
et
al
yang
et
al
nmr
data
compound
previous
report
chuang
et
al
identif
previous
report
wu
et
al
yang
et
al
novel
concis
rout
high
yield
develop
synthes
novel
intermedi
intermedi
synthes
scheme
high
yieldsynthesi
scheme
publish
elsewher
two
intermedi
use
synthesi
consequ
two
natur
occur
compound
rao
boehmeriasin
luo
et
al
chemic
synthes
first
time
compound
novel
compound
deoxypergularinin
similarli
synthes
collect
compound
synthes
consist
moieti
phenanthren
indolizidin
phenanthroquinolizidin
phenanthren
quinolizidin
phenanthroindolizidin
phenanthroquinolizidin
tri
tetra
pentamethoxyl
moieti
phenanthren
without
hydroxyl
oacat
format
noxid
indolizidinequinolizidin
moieti
shown
intermedi
complet
synthes
slight
modif
report
method
chuang
et
al
synthes
compound
verifi
hplcm
data
shown
h
nmr
c
nmr
compound
tylophorin
noxid
natur
occur
compound
noxid
novel
compound
synthes
use
respect
react
h
follow
compound
mg
mmol
dissolv
aceton
ml
dropwis
addit
h
ml
mmol
result
solut
stir
room
temperatur
h
extract
chcl
ml
organ
phase
combin
dri
evapor
final
residu
purifi
column
chromatographi
silica
gel
ch
cl
meoh
give
compound
yield
novel
compound
yield
compound
deriv
chemic
synthesi
racem
except
compound
see
fig
chemic
structur
supplementari
data
physic
properti
synthes
tylophorin
compound
tylophorin
compound
obtain
methanol
extract
indica
ovata
purifi
chromatographi
seri
includ
silicagel
opencolumn
chromatographi
hplc
detail
isol
purif
publish
elsewher
lcm
hreim
h
nmr
c
nmr
dept
cosi
noesi
hsqc
hmbc
use
identifi
verifi
structur
obtain
tylophorin
analogu
data
shown
except
h
nmr
c
nmr
compound
valid
tylophorin
tylophorinin
h
nmr
c
nmr
data
previous
report
abe
et
al
chuang
et
al
nordland
njorog
zeng
chemler
zhen
et
al
tylophorin
analogu
semisynthes
mix
acet
anhydrid
ac
pyridin
overnight
stir
room
temperatur
govindachari
et
al
valid
h
nmr
c
nmr
data
previous
report
govindachari
et
al
zhen
et
al
detail
inform
compound
publish
elsewher
compound
identifi
komatsu
et
al
see
fig
chemic
structur
supplementari
data
physic
properti
isol
tylophorin
compound
laboratori
constraint
biosafeti
level
st
cell
infect
tgev
vero
cell
infect
human
cov
use
surrog
system
screen
agent
inhibit
activ
sar
cov
laboratori
establish
cellbas
pro
enzymat
assay
tgev
search
antivir
agent
tgev
sar
cov
benzothiazolium
compound
eg
found
inhibit
pro
enzymat
activ
tgev
sar
cov
hit
compound
obtain
ifa
screen
agent
tgev
may
reflect
highli
conserv
substrat
specif
structur
cov
pro
activ
benzothiazolium
compound
inhibit
tgev
ec
valu
maxim
inhibit
concentr
ic
valu
rang
yang
et
al
tylophorin
compound
includ
compound
librari
primari
ifa
screen
agent
tgev
sar
cov
shortag
compound
resourc
time
although
carri
studi
antiinflammatori
anticancer
mechan
tylophorin
wu
et
al
yang
et
al
accident
laboratori
found
tylophorin
potent
inhibit
tgev
replic
assess
ifa
antibodi
n
protein
tgev
ec
valu
compound
nm
respect
fig
tabl
howev
compound
significantli
inhibit
tgev
sar
cov
pro
enzymat
activ
data
shown
moreov
two
compound
exert
longlast
least
hpi
inhibit
viru
cpe
tgevinfect
st
cell
contrast
tgevinfect
st
cell
without
compound
treatment
exhibit
signific
cpe
hpi
fig
examin
apoptosi
indic
tgevinfect
st
cell
activ
caspas
found
good
agreement
anticp
effect
tylophorin
fig
effect
compound
inhibit
viru
yield
also
examin
realtim
quantit
pcr
two
primer
pair
correspond
pro
n
protein
region
end
end
tgev
genom
respect
brian
baric
sawicki
sawicki
tgev
viru
yield
profoundli
reduc
compound
ec
valu
compar
measur
ifa
fig
moreov
compound
prophylact
therapeut
inhib
ite
tgev
replic
pre
co
posttreat
tgevinfect
st
cell
potent
reduc
fluoresc
stain
fig
thu
compound
strongli
protect
st
cell
tgev
infect
addit
tylophorin
anoth
compound
obtain
analyz
antitgev
activ
ec
valu
cytotox
st
cell
cc
valu
tabl
select
index
si
valu
calcul
cc
ec
dehydrotylophorin
analogu
least
inhibitori
compound
test
ec
valu
rang
nm
tabl
analogu
moder
inhibitor
tgev
replic
ec
valu
rang
nm
tabl
tylophorin
analogu
potent
select
inhibitor
viru
replic
ec
valu
nm
high
si
valu
tabl
moreov
antitgev
activ
compound
deriv
cpe
assay
consist
ec
valu
determin
ifa
fig
b
tabl
potent
analogu
exert
prolong
inhibit
cpe
inhibit
appear
cpe
least
h
fig
b
thu
block
tgev
replic
induc
apoptosi
indic
reduct
tgev
n
protein
express
caspas
activ
infect
st
cell
fig
effort
initi
identifi
smallmolecul
agent
antisar
cov
infect
thu
far
inhibitor
target
sar
cov
proteas
report
ic
valu
rang
sar
cov
papainlik
proteas
nm
rang
howev
antienzymat
activ
inhibitor
may
exhibit
correspond
antisar
cov
activ
cell
ghosh
et
al
use
porcin
tgev
surrog
system
search
potenti
antisar
cov
agent
yang
et
al
test
tylophorin
compound
anticp
activ
induc
sar
cov
urbani
strain
vero
cell
compound
found
profound
activ
ec
valu
rang
select
index
si
valu
determin
cpe
assay
microscop
observ
wherea
ec
valu
rang
si
valu
determin
neutral
red
uptak
assay
respect
tabl
cpe
assay
vero
cell
induc
sar
cov
take
day
barnard
et
al
tylophorin
compound
report
inhibit
cell
growth
lee
et
al
wu
et
al
day
assay
final
cell
number
would
differ
cell
volum
usual
larger
treat
tylophorin
compound
unpublish
data
also
manifest
compar
cell
number
cell
size
sar
cov
infect
vero
cell
treat
compound
without
sar
infect
control
equal
area
microscop
fig
therefor
conceiv
lower
si
valu
obtain
neutral
red
uptak
assay
determin
rel
cell
number
cpe
assay
observ
microscop
compound
also
decreas
format
larg
syncytia
andor
multinucl
giant
cell
result
virusinduc
fusion
cell
membran
dosedepend
manner
fig
thu
tylophorin
compound
potent
small
molecul
antisar
cov
protect
cell
system
increas
planar
rigid
structur
dehydrogen
indolizidinequinolizidin
moieti
compound
suggest
respons
moder
least
activ
antitgev
compar
potent
compound
structureact
relat
also
found
stand
antiinflammatori
anticancer
activ
yang
et
al
among
potent
tylophorin
analogu
inhibit
tgev
compound
hydroxyl
group
phenanthren
moieti
ec
valu
compound
nm
respect
thu
hydroxyl
group
contribut
significantli
inhibitori
activ
exhibit
tylophorin
analogu
howev
introduct
oacgroup
posit
decreas
activ
compar
compound
hydrogen
hydroxyl
groupreplac
respect
although
similar
potenc
differ
cytotox
thu
select
tabl
import
concern
futur
drug
develop
moreov
introduct
methoxyl
group
posit
tylophorin
decreas
inhibitori
activ
parent
compound
indolizidin
quinolizidin
counterpart
similarli
replac
methoxyl
hydrogen
group
posit
tylophorin
decreas
inhibitori
activ
indolizidin
quinolizidin
counterpart
lesser
extent
addit
compound
oxygen
atom
introduc
reactiv
nitrogen
form
noxid
compar
respect
exert
less
potenc
introduct
noxid
indolizidinequinolizidin
moieti
chang
nitrogen
reac
tiviti
might
affect
posit
project
hydrogen
atom
potenc
dehydrogen
moieti
profoundli
decreas
activ
eg
similarli
phenanthroquinolizidin
potent
phenanthroindolizidin
counterpart
antisar
cov
activ
hydroxyl
group
contribut
significantli
inhibitori
activ
exhibit
compound
tylophorin
main
activ
constitu
indica
use
tradit
herbal
medicin
india
taken
dri
leav
antiasthma
exampl
perform
pharmacokinet
studi
determin
oral
bioavail
paramet
tylophorin
quinolizidin
counterpart
valu
determin
visual
microscopi
neutral
red
uptak
assay
test
plate
antisar
covinduc
cytopath
effect
cytotox
respect
indic
compound
vero
cell
describ
barnard
et
al
si
valu
also
calcul
maxim
effect
concentr
b
maxim
cytotox
concentr
c
si
select
index
ad
equal
volum
nearconflu
cell
monolay
vero
cell
cultur
plate
moi
use
rang
produc
viru
cytopath
effect
cell
viru
control
well
within
day
along
mock
infect
control
plate
incub
c
cell
viru
control
well
show
complet
viral
cpe
observ
light
microscopi
stain
neutral
red
describ
barnard
et
al
equal
field
area
treatment
shown
microscop
observ
magnif
methoxycryptopleurin
tabl
synthet
compound
natur
occur
yang
et
al
intraven
administr
mgkg
total
bodi
clearanc
mlminkg
respect
volum
distribut
steadi
state
v
ss
lkg
respect
suggest
wide
distribut
compound
extravascular
tissu
appar
elimin
halflif
intraven
dose
long
h
compound
oral
administr
compound
rapidli
absorb
c
max
valu
ngml
reach
h
respect
administr
oral
bioavail
estim
compar
suggest
conserv
oral
bioavail
compound
plant
materi
great
resourc
human
therapeut
medicin
use
altern
medicin
great
reservoir
discoveri
natur
occur
compound
develop
therapeut
agent
content
phenanthroindolizidin
differ
tylophora
plant
could
slightli
vari
harvest
season
locat
instanc
tylophorin
main
activ
constitu
indica
gopalakrishnan
et
al
tylophorinin
atrofolliculata
huang
et
al
ovata
unpublish
data
addit
potenc
toxic
phenanthroindolizidin
may
vari
depend
plant
sourc
tabl
unpublish
data
thu
dose
achiev
efficaci
select
must
investig
part
drug
develop
process
regardless
formul
pure
compound
herbal
medicin
studi
first
report
compar
pharmacokinet
natur
occur
tylophorin
synthes
demonstr
good
oral
bioavail
efficaci
select
oral
bioavail
tylophorin
compound
report
effort
develop
optim
druglik
deriv
compound
warrant
si
valu
microscop
observ
result
tabl
differ
compar
tabl
pharmacokinet
properti
tylophorin
rat
paramet
valu
obtain
tgev
assay
valu
obtain
sar
cov
assay
neutral
red
uptak
due
entir
differ
cell
differ
speci
origin
use
assay
length
time
compound
expos
cell
differ
assay
type
cytotox
test
use
differ
compound
expos
vero
cell
sar
cov
test
h
give
compound
longer
becom
toxic
cell
neutral
red
uptak
assay
use
sensit
evalu
cytotox
growth
inhibit
smee
et
al
alway
tissu
tissu
differ
assess
cytotox
smee
et
al
cell
deriv
swine
testicular
tissu
appar
less
sensit
toxic
cell
deriv
monkey
kidney
main
effect
tylophorin
compound
inhibit
tgev
replic
st
cell
therebi
block
tgevinduc
apoptosi
signal
st
cell
fig
tylophorin
compound
may
administ
prophylact
therapeut
administr
regimen
greatli
inhibit
tgev
replic
measur
ifa
fig
therefor
tylophorin
compound
like
inhibit
tgev
replic
event
virus
enter
cell
moreov
abil
compound
inhibit
coronavirus
sar
cov
vero
cell
tabl
fig
increas
surviv
rate
mice
infect
mhvjhm
data
shown
suggest
compound
inhibit
common
highli
conserv
target
among
coronavirus
involv
coronavir
transcript
complex
eg
rdrp
helicas
n
protein
etc
common
cellular
factor
crucial
coronavir
replic
detail
mechan
studi
effect
tylophorin
compound
molecular
level
tgev
replic
infect
st
cell
investig
develop
optim
phenanthroindolizidin
therapeut
drug
varieti
tylophorin
deriv
must
expand
provid
fundament
data
better
understand
relationship
structur
activ
synthes
isol
natur
sourc
obtain
varieti
tylophorin
cryptopleurin
compound
describ
previous
unreport
anticoronaviru
activ
tylophorin
compound
provid
insight
structureact
relat
moreov
compound
clinic
relev
potent
activ
low
nanomolar
rang
tabl
high
oral
bioavail
tabl
activ
tylophorin
compound
abl
safe
achiev
clinic
accept
dose
collect
tylophorin
compound
tradit
herb
plant
compound
deriv
consid
use
sourc
anticoronaviru
inhibitor
coronaviru
epidem
pandem
